Abstract: The present invention concerns the methods and compositions for evaluating the risk of ironotecan toxicity in a cancer patient based on the genotype of the patient at position ?3156 of the UGT1A1 gene or at any position in linkage disequilibrium with the ?3156 variant.

Abstract: The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.

Abstract: The present invention concerns the methods and compositions for evaluating the risk of ironotecan toxicity in a cancer patient based on the genotype of the patient at position ?3156 of the UGT1A1 gene or at any position in linkage disequilibrium with the ?3156 variant.

Abstract: The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.

Abstract: Various embodiments of the invention include methods and compositions for evaluating the risk of irinotecan toxicity in a patient. In certain embodiments, the methods include detecting a promoter polymorphism in one or both UGT1A1 genes of the patient. In particular embodiments the promoter polymorphism is a single nucleotide polymorphism and may be in linkage disequilibrium with a UGT1A1 (TA)n repeat. The methods may include obtaining a nucleic acid sample from the patient and detecting the presence or absence of a promoter polymorphism. The promoter polymorphism may be at nucleotide position −3440, −3401, −3279, −3177, −3175, or −3156 from the UGT1A1 gene transcriptional start site. The number of TA repeats can be 5, 6, 7, 8 more TA repeats. In particular embodiments, the promoter polymorphism is a −3440C>A, −3401T>C, −3279G>T, −3177C>G, −3175A>G, −3156G>A polymorphism or any combination thereof.

Abstract: The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.

Abstract: The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.

Abstract: The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.

Abstract: The present invention is, directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.